Actinium Pharmaceuticals Inc. (Delaware)

8.13-0.0400-0.49%Vol 175.53K1Y Perf 38.08%
Apr 9th, 2021 16:00 DELAYED
BID8.10 ASK8.15
Open8.17 Previous Close8.17
Pre-Market- After-Market8.15
 - -  0.02 0.25%
Target Price
38.33 
Analyst Rating
Strong Buy 1.00
Potential %
371.46 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap110.46M 
Earnings Rating
Buy
Price Range Ratio 52W %
23.17 
Earnings Date
5th Jan 2021

Today's Price Range

7.978.26

52W Range

4.7119.47

5 Year PE Ratio Range

-1.60-2.10

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
0.87%
1 Month
0.87%
3 Months
-1.33%
6 Months
-22.87%
1 Year
38.08%
3 Years
-26.76%
5 Years
-86.38%
10 Years
-

TickerPriceChg.Chg.%
ATNM8.13-0.0400-0.49
AAPL132.992.63002.02
GOOG2 285.8820.44000.90
MSFT255.852.60001.03
XOM55.87-0.1300-0.23
WFC40.500.47001.17
JNJ161.25-1.7200-1.06
FB312.46-0.5600-0.18
GE13.600.15001.12
JPM156.281.16000.75
Earnings HistoryEstimateReportedSurprise %
Q03 2019-1.20-1.200.00
Q02 2019--0.90-
Q01 2019-1.80-1.5016.67
Q04 2018-0.06-0.060.00
Q02 2018-0.06-0.0433.33
Q02 2017-0.14-0.1214.29
Q01 2017-0.13-0.14-7.69
Q02 2016-0.15-0.150.00
Earnings Per EndEstimateRevision %Trend
12/2020 FY-2.010.00-
3/2021 QR-0.510.00-
6/2021 QR-0.630.00-
12/2021 FY-1.810.00-
Next Report Date-
Estimated EPS Next Report-0.59
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume175.53K
Shares Outstanding13.59M
Trades Count1.13K
Dollar Volume3.66M
Avg. Volume401.79K
Avg. Weekly Volume236.37K
Avg. Monthly Volume302.82K
Avg. Quarterly Volume382.35K

Actinium Pharmaceuticals Inc. (Delaware) (AMEX: ATNM) stock closed at 8.13 per share at the end of the most recent trading day (a -0.49% change compared to the prior day closing price) with a volume of 185.67K shares and market capitalization of 110.46M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 25 people. Actinium Pharmaceuticals Inc. (Delaware) CEO is Sandesh Seth.

The one-year performance of Actinium Pharmaceuticals Inc. (Delaware) stock is 38.08%, while year-to-date (YTD) performance is 4.23%. ATNM stock has a five-year performance of -86.38%. Its 52-week range is between 4.71 and 19.47, which gives ATNM stock a 52-week price range ratio of 23.17%

Actinium Pharmaceuticals Inc. (Delaware) currently has a PE ratio of -3.10, a price-to-book (PB) ratio of 1.69, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -56.17%, a ROC of -71.64% and a ROE of -65.86%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Actinium Pharmaceuticals Inc. (Delaware), there were 1 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.59 for the next earnings report. Actinium Pharmaceuticals Inc. (Delaware)’s next earnings report date is -.

The consensus rating of Wall Street analysts for Actinium Pharmaceuticals Inc. (Delaware) is Strong Buy (1), with a target price of $38.33, which is +371.46% compared to the current price. The earnings rating for Actinium Pharmaceuticals Inc. (Delaware) stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Actinium Pharmaceuticals Inc. (Delaware) has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Actinium Pharmaceuticals Inc. (Delaware) has a Sell technical analysis rating based on Technical Indicators (ADX : 23.36, ATR14 : 0.56, CCI20 : -54.98, Chaikin Money Flow : -0.11, MACD : -0.27, Money Flow Index : 27.64, ROC : -2.42, RSI : 38.50, STOCH (14,3) : 46.76, STOCH RSI : 1.00, UO : 54.49, Williams %R : -53.24), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Actinium Pharmaceuticals Inc. (Delaware) in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its most advanced products are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

CEO: Sandesh Seth

Telephone: +1 646 677-3870

Address: 275 Madison Avenue, New York 10016, NY, US

Number of employees: 25

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

59%41%

Bearish Bullish

56%44%

Bearish Bullish

51%49%

News

Stocktwits